Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, ...
LSTA Stock | USD 2.75 1.15 29.49% |
About 62% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lisata |
urlEnveric Biosciencesurl, Inc. , a biotechnology company dedicated to the development of novel neuro
Read at gurufocus.com
Lisata Therapeutics Fundamental Analysis
We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Lisata Therapeutics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Lisata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.
Peers
Lisata Therapeutics Related Equities
PULM | Pulmatrix | 12.77 | ||||
IMNN | Imunon | 7.87 | ||||
TPST | Tempest Therapeutics | 4.55 | ||||
RZLT | Rezolute | 3.74 | ||||
BPTH | Bio Path | 3.57 | ||||
CADL | Candel Therapeutics | 3.22 | ||||
LIXT | Lixte Biotechnology | 2.51 | ||||
PTIX | Protagenic Therapeutics | 2.44 | ||||
MBRX | Moleculin Biotech | 0.57 | ||||
XOMAO | XOMA | 0.28 | ||||
GLUE | Monte Rosa | 0.54 | ||||
ANTX | AN2 Therapeutics | 0.79 |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |